A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
Clinical trial NCT07729033 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07729033
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2027-12-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.